Announcements Trials
Browse Landscape

Status

Recruiting 475Completed 196Active not recruiting 174Not yet recruiting 112Terminated 31Enrolling by invitation 31Withdrawn 10Suspended 9Available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Sarcoma 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Osteosarcoma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic Syndromes 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Neoplasms × 90 days × Clear all
NCT06761976 2026-06-04

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Bayer

Available
Tumor-Agnostic

Neoplasms

NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Agenus Inc.

Available
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡